Hudson Canyon Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Hudson Canyon Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,440	Closed	-$1.39M	–	52
2025 Q2	$1.39M	Buy	3,440 +343	+11%	+$143K	0.87%	51
2025 Q1	$1.54M	Hold	3,097	–	–	1.09%	48
2024 Q4	$1.61M	Hold	3,097	–	–	1.05%	47
2024 Q3	$1.92M	Hold	3,097	–	–	1.24%	38
2024 Q2	$1.71M	Sell	3,097 -380	-11%	-$218K	1.16%	37
2024 Q1	$2.02M	Hold	3,477	–	–	1.3%	35
2023 Q4	$1.85M	Sell	3,477 -77	-2%	-$37.3K	1.34%	39
2023 Q3	$1.8M	Hold	3,554	–	–	1.47%	29
2023 Q2	$1.85M	Sell	3,554 -112	-3%	-$60.4K	1.46%	29
2023 Q1	$2.11M	Sell	3,666 -159	-4%	-$89.6K	1.77%	15
2022 Q4	$2.11M	Sell	3,825 -83	-2%	-$44K	1.94%	12
2022 Q3	$1.98M	Hold	3,908	–	–	1.97%	15
2022 Q2	$2.12M	Buy	3,908 +41	+1%	+$22.6K	2.05%	11
2022 Q1	$2.28M	Hold	3,867	–	–	1.8%	16
2021 Q4	$2.58M	Sell	3,867 -376	-9%	-$235K	1.87%	10
2021 Q3	$2.42M	Sell	4,243 -157	-4%	-$86.2K	1.87%	13
2021 Q2	$2.22M	Buy	+4,400	New	+$2.08M	1.66%	24

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Hudson Canyon Capital Management's TMO Position: Q3 2025 in Review

Hudson Canyon Capital Management sold out of Thermo Fisher Scientific (TMO) in Q3 2025, closing a stake of 3,440 shares — an estimated $1.39M sold.

Hudson Canyon Capital Management first reported a position in TMO in Q2 2021 and held it in 17 quarters. The position peaked at $2.58M in Q4 2021. 2,508 funds tracked by Wall St. Rank hold TMO as of Q3 2025.

Hudson Canyon Capital Management reported no remaining Thermo Fisher Scientific position as of Q3 2025 after selling out during the quarter.
Hudson Canyon Capital Management sold 3,440 Thermo Fisher Scientific shares in Q3 2025, an estimated $1.39M.
Hudson Canyon Capital Management first reported a position in Thermo Fisher Scientific in Q2 2021 and held it in 17 quarters.
Hudson Canyon Capital Management's Thermo Fisher Scientific position peaked at $2.58M in Q4 2021.
2,508 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2025.

Based on Hudson Canyon Capital Management's 13F filing for Q3 2025, filed 5 Nov 2025.